Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.10 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.10, Zacks reports. Coloplast A/S had a net margin of 9.68% and a return on equity of 38.81%. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion.
Coloplast A/S Stock Performance
Shares of OTCMKTS CLPBY opened at $6.95 on Thursday. The business’s 50-day simple moving average is $6.26 and its 200-day simple moving average is $6.65. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.09 and a current ratio of 1.75. Coloplast A/S has a 52 week low of $5.64 and a 52 week high of $10.03. The firm has a market cap of $15.66 billion, a price-to-earnings ratio of 36.58, a P/E/G ratio of 2.15 and a beta of 0.13.
Wall Street Analysts Forecast Growth
Separately, Kepler Capital Markets raised Coloplast A/S to a “strong-buy” rating in a research report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.
About Coloplast A/S
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Further Reading
- Five stocks we like better than Coloplast A/S
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
